Tuesday, November 24, 2009, 3:06pm EST - Canadian Markets close in 54 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Insmed Incorporated (INSM)

 At 14:51 EST: 0.7971 USD  Up 0.0169 (2.17%)  
MORE ON INSM
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Insmed, Inc. (NCM:INSM) Delayed quote dataEdit
Last Trade: 0.7971 USD
Trade Time: 2:51PM EST
Change: Up 0.0169 (2.17%)
Prev Close: 0.7802
Open: 0.7803
Bid: 0.7903 x 300
Ask: 0.7971 x 900
1y Target Est: 2.00
Day's Range: 0.78 - 0.79
52wk Range: 0.40 - 2.57
Volume: 303,107
Avg Vol (3m): 598,540
Market Cap: 103.79M
P/E (ttm): N/A
EPS (ttm): -0.348
Div & Yield: N/A (N/A%)
Insmed Incorporated (INSM)
1d  5d  3m  6m  1y  2y  5y  max 
 Add INSM to Portfolio   Download Data

HEADLINES
• INSMED INC Financials
EDGAR Online Financials (Fri, Nov 13)
• Insmed Still Looks Very Undervalued
at Seeking Alpha (Mon, Nov 9)
• INSMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online (Fri, Nov 6)
• Insmed Incorporated Earnings Call scheduled for 8:30 am ET today
CCBN (Fri, Nov 6)
• Specialty Pharma Stock Picks From David Amsellem Of Piper Jaffray
Wall Street Transcript (Fri, Nov 6)
• Q3 2009 Insmed Incorporated Earnings Release - Before Market Open
CCBN (Fri, Nov 6)
• Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2009
PRNewswire (Fri, Nov 6)
• Old School Value Stock Portfolio Performance October 2009
at Seeking Alpha (Tue, Nov 3)
• Insmed To Host Third Quarter 2009 Conference Call
PRNewswire (Thu, Oct 22)
• "Best In Class" Formulation Of Fentanyl Seen As Breakthrough Treatment By Ladenburg Thalmann Analyst
Wall Street Transcript (Tue, Oct 20)
• Portfolio Update: Holdings, Performance
at Seeking Alpha (Sun, Oct 4)
• Sirius Breaks the Buck
at Motley Fool (Fri, Sep 18)
• INSMED INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transf
EDGAR Online (Wed, Sep 16)
More Headlines for INSM...
ANALYST
EPS Est (next year) (Dec-07) : N/A
EPS Est (in 2 years) (Dec-08) : N/A
Avg Rec (current)*: 2.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Insmed Incorporated, a biopharmaceutical company, engages in the development and commercialization of drugs to treat metabolic diseases, endocrine disorders, and oncology.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices